Evidence map›Paper›PMID 37357771›Full record

ArticleHypertension (Dallas, Tex. : 1979)2023

Characterization of Individuals With Apparent Resistant Hypertension Using Contemporary Guidelines: Insights From CV-QUIC.

Joseph E Ebinger, Ty J Gluckman, Jose Magraner, Shih Ting Chiu, Deanna Rider, Chelsey Thomas, Sandeep R Das, P Michael Ho, Satya Shreenivas, Steven Bradley

Open access · greenAbstract read
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Joseph E EbingerDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.E.E., J.M.).ORCID 0000-0002-0587-1572
Ty J GluckmanCenter for Cardiovascular Analytics, Research and Data Science, Providence Heart Institute, Providence St. Joseph Health, Portland, OR (T.J.G., S.T.C.).
Jose MagranerDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (J.E.E., J.M.).
Shih Ting ChiuCenter for Cardiovascular Analytics, Research and Data Science, Providence Heart Institute, Providence St. Joseph Health, Portland, OR (T.J.G., S.T.C.).
Deanna RiderProvidence Research Network, Missoula, MT (D.R.).
Chelsey ThomasHealth Catalyst, Minneapolis, MN (C.T.).
Sandeep R DasUniversity of Texas Southwestern Medical Center and Center for Innovation and Value at Parkland, Dallas (S.R.D.).ORCID 0000-0002-8454-1925
P Michael HoUniversity of Colorado School of Medicine, VA Eastern Colorado Health Care System, Aurora (P.M.H.).ORCID 0000-0002-7775-6266
Satya ShreenivasLindner Center for Research, The Christ Hospital, Cincinnati, OH (S.S.).
Steven BradleyHealthcare Delivery Innovation Center, Minneapolis Heart Institute, MN (S.B.).ORCID 0000-0003-4006-6760
Cedars-Sinai Smidt Heart Institute · USSt. Joseph Health System · USChrist Hospital · USCommunity Catalyst · USMinneapolis Heart Institute Foundation · USResearch Network (United States) · USThe University of Texas Southwestern Medical Center · USVA Eastern Colorado Health Care System · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Barber-Pharmacist Coordination to Improve Blood Pressure Management in Black MenR01HL117983 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI ALBERT, CHRISTINE M · 2014 to 2018
$8.6M
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI PHILIPP E SCHERER · 2022 to 2026
$7.4M
Implementation Science to Improve Cardiovascular Health: Leveraging EHR Systems to Advance Care of Resistant HypertensionK23HL153888 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI EBINGER, JOSEPH · 2020 to 2024
$929k
NHLBI NIH HHS K23 HL153888NHLBI NIH HHS R01 HL117983NIDDK NIH HHS P30 DK127984NIH HHS P51 OD011132
6 · The paper itself

Abstract

backgroundApparent resistant hypertension (aRH) carries excess cardiovascular risk beyond nonresistant forms of hypertension; however, our understanding of this at-risk population, as defined by current US practice guidelines, is limited. Accordingly, we sought to evaluate the prevalence, clinical characteristics, and pharmacotherapeutic patterns of patients with aRH using contemporary blood pressure guidance.

methodsWe classified patients at 3 large healthcare systems by hypertensive status using contemporary hypertension guidelines. We subsequently described the demographic and clinical characteristics of patients with aRH and compared these factors among hypertensive patients without aRH and between those with controlled and uncontrolled aRH.

resultsA total of 2 420 468 patients were analyzed, of whom 1 343 489 (55.6%) were hypertensive according to contemporary guidelines. Among hypertensive patients, 11 992 (8.5%) met criteria for aRH, with nearly all assessed comorbid conditions, particularly diabetes and heart failure, being more common in those with aRH. When compared with patients with uncontrolled aRH, those with controlled aRH were more frequently prescribed a beta-blocker, diuretic, and nitrate, with the largest standardized difference observed for a mineralocorticoid receptor antagonist (35.4% versus 10.4%, Cohen D 0.62). Consistent findings were noted in sensitivity analyses using the blood pressure threshold of 140/90 mm Hg.

conclusionsIn an analysis of over 2.4 million individuals, a lower prevalence of aRH was observed than previously reported (12%-15%), but with a high burden of comorbidities. Identification of differences in pharmacotherapy between patients with controlled and uncontrolled aRH, particularly lower rates of mineralocorticoid receptor antagonist use, help define potential opportunities to improve care and lower cardiovascular risk.

Indexed as

Antihypertensive AgentsHypertensionBlood PressureBlood Pressure DeterminationHumansMineralocorticoid Receptor AntagonistsAntihypertensive AgentsMineralocorticoid Receptor Antagonistsangiotensin-converting enzymeblood pressureelectronic health recordepidemiologyhypertension

Identifiers

PMID37357771
PMCPMC10524942
OpenAlexW4382010893

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.